<DOC>
	<DOCNO>NCT01144429</DOCNO>
	<brief_summary>Specific immunotherapy subcutaneous application : Dose find study evaluate correct dose . 4 concentration birch pollen allergen extract apply study . Duration therapy 20 week . Primary criterion Conjunctival Provocation Test ( CPT ) , i.e . comparison treatment arm increase amount quantity allergen provoke positive CPT end treatment .</brief_summary>
	<brief_title>Dose Finding Study Depigoid Birch : 4 Doses Patients With Allergic Rhinitis/Rhinoconjunctivitis +-Asthma</brief_title>
	<detailed_description>This dose find study therapeutic study . Patients receive 4-weekly interval 5x injection 0,5 ml solution modify birch pollen extract outside pollen season . The primary endpoint therefore therapeutic effect specific immunotherapy ( effect symptom allergy birch pollen season ) effect CPT . Acc . EMEA `` Guideline clinical development product specific immunotherapy treatment allergic disease '' provocation test accept primary outcome dose-finding study . For CPT increase dos birch pollen solution apply eye characteristic symptom ( eye redness , weep , itch burn nose dripping/blockage ) assess : 0 = absent , 1=mild , 2=moderate , 3=severe ) . At score value &gt; = 5/concentration test consider positive finish . It expect end study high dos necessary provoke positive CPT . Furthermore comparative evaluation safety data ( AEs ) different dosage group important parameter evaluation outcome study .</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Rhinitis , Allergic</mesh_term>
	<mesh_term>Rhinitis</mesh_term>
	<mesh_term>Conjunctivitis</mesh_term>
	<criteria>1 . Patients provide appropriately sign date informed consent prior study specific examination , 2 . Patients must ≥ 18 ≤ 70 year age Visit 1 , 3 . Patients must perception disease activity least 30 mm 100 mm visual analogue scale ( VAS ) , 4 . Patients must FEV1 PEF value &gt; 80 % predict normal value ( PEF : high result 3 measurement ) , 5 . Patients must complain allergic rhinitis and/or rhinoconjunctivitis symptom least 2 year without intermittent asthma symptom , cause clinical sensitization birch pollen , 6 . IgEmediated sensitization verify : suggestive medical history , specific IgE birch pollen ( CAPRast ≥ 2 ) , positive SPT birch pollen ( SPT consider positive result wheal diameter least 3 mm least size histamine reference ) , positive CPT birch pollen concentration 10,000 SQunits/mL . Special criteria patient coallergies 7 . Patients suffer typical symptom coallergens , 8 . Specific CAPRAST coallergens &lt; CAPRAST birch pollen ( difference ≥ 2 ) , patient coallergens animal dander randomize even CAP RAST difference &lt; 2 , must expose specific allergen , 9 . Result SPT coallergens &lt; result SPT birch pollen . 1 . Acute chronic conjunctivitis , 2 . Infectious conjunctivitis , 3 . History significant clinical manifestation allergy result sensitization grass weed pollen perennial allergen ( e.g . house dust mite ) , 4 . Symptoms due coallergies , 5 . Persistent asthma , accord Global Initiative Asthma ( GINA ) Guidelines , 6 . Acute chronic inflammatory infectious airway disease include recurrent acute chronic sinusitis , 7 . Chronic structural disease lung ( e.g . emphysema bronchiectasis ) , 8 . Diseases immune system include autoimmune immune deficiency , 9 . Any disease , prohibit use adrenaline ( e.g . hyperthyroidism ) , 10 . Severe uncontrolled disease could increase risk patient participate study , include limited following : cardiovascular insufficiency , severe unstable lung disease , endocrine disease , clinically significant renal hepatic disease , hematological disorder , 11 . Any malignant disease previous 5 year , 12 . Any significant abnormal laboratory parameter alteration vital sign could increase risk study patient , 13 . Alcohol , drug , medication abuse within past year , 14 . Severe psychiatric , psychological , neurological disorder , 15 . Use immunotherapy birch pollen within last 5 year , 16 . Topical systemic treatment βblockers , 17 . Treatment substance interfere immune system within 1 week prior Visit 2 , 18 . Use tranquillizer psychoactive drug within 1 week prior Visit 1 , 19 . Use systemic corticosteroid within 3 month prior Visit 1 , 20 . Immunization vaccine within 7 day prior Visit 2 , 21 . Patients hypersensitivity excipients investigational medicinal product , 22 . Patients expect noncompliant and/or cooperative , 23 . Exposure investigational drug within one month 6 half life , 24 . Patients already participate study , 25 . Patients employee institution , 1st grade relative , partner investigator , 26 . Any donation germ cell , blood , organ , bone marrow course study , 27 . Patients contractually capable , 28 . Nursing ( lactate ) woman positive pregnancy test Visit 1 . 29 . Persons jurisdictional governmentally institutionalize .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>Allergic Rhinitis +- intermittent asthma</keyword>
	<keyword>Allergic Rhinoconjunctivitis +- intermittent asthma</keyword>
	<keyword>Specific Immunotherapy</keyword>
</DOC>